title: Raising the bar: the curative potential of human cancer immunotherapy.
abstract: Immunotherapy with interleukin-2 can cure 5 to 10% of patients with metastatic melanoma and renal cancer. Recent adoptive cell transfer (ACT) immunotherapies have improved cure rates in metastatic melanoma to 20 to 40%. Genetic engineering of T cells to express conventional alpha/beta T cell receptors or antibody-based chimeric antigen receptors provides an opportunity to extend ACT to patients with common epithelial cancers.
authors.affiliation: Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. sar@nih.gov
authors.forename: Steven A
authors.initials: SA
authors.lastname: Rosenberg
mesh_terms: D019496:Cancer Vaccines / Q000276:immunology; D006801:Humans; D007167:Immunotherapy; D008545:Melanoma / Q000276:immunology / Q000473:pathology / Q000628:therapy; D009362:Neoplasm Metastasis / Q000628:therapy; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy*; D014611:Vaccination
chemical_list: D019496:Cancer Vaccines